260 related articles for article (PubMed ID: 20461046)
21. Novel biomarkers, dysregulated epigenetics, and therapy in cutaneous T-cell lymphoma.
Wong HK
Discov Med; 2013 Sep; 16(87):71-8. PubMed ID: 23998443
[TBL] [Abstract][Full Text] [Related]
22. Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma.
Weng WK; Armstrong R; Arai S; Desmarais C; Hoppe R; Kim YH
Sci Transl Med; 2013 Dec; 5(214):214ra171. PubMed ID: 24307695
[TBL] [Abstract][Full Text] [Related]
23. Transition of Sézary syndrome into mycosis fungoides after complete clinical and molecular remission under extracorporeal photophoresis.
Assaf C; Hummel M; Zemlin M; Steinhoff M; Geilen CC; Stein H; Orfanos CE
J Clin Pathol; 2004 Dec; 57(12):1325-8. PubMed ID: 15563677
[TBL] [Abstract][Full Text] [Related]
24. Osteonecrosis of the Jaw in Association With Chemotherapy in the Setting of Cutaneous T-Cell Lymphoma.
DeSesa CR; Appugounder S; Haberland C; Johnson MP
J Oral Maxillofac Surg; 2016 Feb; 74(2):292-301. PubMed ID: 26296596
[TBL] [Abstract][Full Text] [Related]
25. Sézary syndrome without erythroderma: A case report and review of published work.
Kamijo H; Miyagaki T; Norimatsu Y; Shishido-Takahashi N; Kuzumi A; Asano Y; Sato S
J Dermatol; 2019 Jan; 46(1):61-64. PubMed ID: 30379353
[TBL] [Abstract][Full Text] [Related]
26. Molecular cytogenetics in the study of cutaneous T-cell lymphomas (CTCL).
Karenko L; Hahtola S; Ranki A
Cytogenet Genome Res; 2007; 118(2-4):353-61. PubMed ID: 18000390
[TBL] [Abstract][Full Text] [Related]
27. The expression of cell adhesion molecule 1 and its splicing variants in Sézary cells and cell lines from cutaneous T-cell lymphoma.
Yamaguchi M; Morizane S; Hamada T; Miyake T; Sugaya M; Iwata H; Fujii K; Haramoto-Shiratsuki R; Nakagawa Y; Miura M; Ohshima K; Morishita K; Takahashi T; Imada M; Okada K; Uehara J; Sowa-Osako J; Iwatsuki K
J Dermatol; 2019 Nov; 46(11):967-977. PubMed ID: 31515833
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sézary syndrome.
Klemke CD; Mansmann U; Poenitz N; Dippel E; Goerdt S
Br J Dermatol; 2005 Jul; 153(1):118-24. PubMed ID: 16029336
[TBL] [Abstract][Full Text] [Related]
29. Prevalence and treatment of palmoplantar keratoderma and tinea pedis in patients with Sézary syndrome.
Martin SJ; Duvic M
Int J Dermatol; 2012 Oct; 51(10):1195-8. PubMed ID: 22994666
[TBL] [Abstract][Full Text] [Related]
30. A modified staging classification for cutaneous T-cell lymphoma.
Kashani-Sabet M; McMillan A; Zackheim HS
J Am Acad Dermatol; 2001 Nov; 45(5):700-6. PubMed ID: 11606919
[TBL] [Abstract][Full Text] [Related]
31. Prevalence and severity of pruritus in cutaneous T cell lymphoma.
Vij A; Duvic M
Int J Dermatol; 2012 Aug; 51(8):930-4. PubMed ID: 22788808
[TBL] [Abstract][Full Text] [Related]
32. Primary cutaneous T-cell lymphoma: clinicopathological features and prognostic parameters of 35 cases other than mycosis fungoides and CD30-positive large cell lymphoma.
Beljaards RC; Meijer CJ; Van der Putte SC; Hollema H; Geerts ML; Bezemer PD; Willemze R
J Pathol; 1994 Jan; 172(1):53-60. PubMed ID: 7931828
[TBL] [Abstract][Full Text] [Related]
33. Incidence of primary cutaneous T-cell lymphoma in Norway.
Saunes M; Nilsen TI; Johannesen TB
Br J Dermatol; 2009 Feb; 160(2):376-9. PubMed ID: 18808419
[TBL] [Abstract][Full Text] [Related]
34. Sustained remission of Sézary syndrome.
Bouwhuis SA; McEvoy MT; Davis MD
Eur J Dermatol; 2002; 12(3):287-90. PubMed ID: 11978575
[TBL] [Abstract][Full Text] [Related]
35. Cutaneous tumor cell load correlates with survival in patients with Sézary syndrome.
Booken N; Nicolay JP; Weiss C; Klemke CD
J Dtsch Dermatol Ges; 2013 Jan; 11(1):67-79. PubMed ID: 23167557
[TBL] [Abstract][Full Text] [Related]
36. High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas.
Valencak J; Schmid K; Trautinger F; Wallnöfer W; Muellauer L; Soleiman A; Knobler R; Haitel A; Pehamberger H; Raderer M
J Dermatol Sci; 2011 Dec; 64(3):185-90. PubMed ID: 21937200
[TBL] [Abstract][Full Text] [Related]
37. Management of mycosis fungoides. Part 1. Diagnosis, staging, and prognosis.
Smith BD; Wilson LD
Oncology (Williston Park); 2003 Sep; 17(9):1281-8. PubMed ID: 14569854
[TBL] [Abstract][Full Text] [Related]
38. Multicolor fluorescence in situ hybridization (SKY) in mycosis fungoides and Sézary syndrome: search for recurrent chromosome abnormalities.
Batista DA; Vonderheid EC; Hawkins A; Morsberger L; Long P; Murphy KM; Griffin CA
Genes Chromosomes Cancer; 2006 Apr; 45(4):383-91. PubMed ID: 16382449
[TBL] [Abstract][Full Text] [Related]
39. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
Vidulich KA; Talpur R; Bassett RL; Duvic M
Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011
[TBL] [Abstract][Full Text] [Related]
40. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
